News & Articles

Test to be integrated in over 5,000 DiaSorin analyzers, allowing physicians to differentiate between bacterial and viral infections

Sanofi and GSK are scaling up the manufacturing of the antigen and adjuvant with the target of producing up to one billion doses in 2021

Data shows 100% concordance with results from Dartmouth-Hitchcock’s lab-based polymerase chain reaction (PCR) test method

Rapid increase in production of VTM and saline will help boost virus testing

A new prognostic tool developed by an international team led by CTI-Bath paves the way for personalized medicine for cancer patients

Watch this on-demand webinar to learn about the latest approaches in single nucleus transcriptomics and ATAC-Seq

The new AI technology will learn from past CT scans of COVID-19 pneumonia patients, reducing the burden on doctors making diagnoses

Ready-to-use kit enables rapid adeno-associated virus (AAV) titer determinations during the manufacture of AAV vectors

FoundationOne Liquid CDx analyzes more than 300 cancer-related genes and multiple genomic signatures to inform treatment decisions for all solid tumor cancers

Combining image analysis with structured reporting, the software aims to improve and accelerate the detection of the virus

Atomwise provides rapid and cost-effective compound screening to address pharmaceutical R&D productivity

Test delivers results in just 15 minutes with no instrumentation, using proven lateral flow technology with demonstrated sensitivity of 97.1% and specificity of 98.5%

The real-time PCR workflow has a capacity of up to 6,000 tests per day per system, and demonstrated 100% agreement with authorized nasopharyngeal assays

The overall goal is to continue to detect and discover critical components in the overall cellular response to COVID-19

Syndromic testing will streamline respiratory infection diagnosis as COVID-19 pandemic collides with start of flu season

Across all populations, BNT162b2 administration was well tolerated with mild to moderate fever in fewer than 20% of the participants

The kits aim to detect traces of SARS-CoV-2 virus on surfaces such as plastics, ceramics and stainless steel

The AccuPlex SARS-CoV-2 molecular controls kit is designed to measure day-to-day assay performance and contains positive materials

The collaboration is the first larger scale production run of Apta-1 as a non-GMP material, intended for use in GLP toxicology studies

The test outperforms other molecular tests with a low detection limit of 15 GEC/reaction (250 GEC/ml of sample) and a robust control system

The consortium aims to determine the dynamics, function and potential for therapeutic intervention of the RNA and protein structures of SARS-CoV-2

IgM assay has 95.51% positive predictive value even when disease incidence is only 3%

The new assays are designed to enable turnaround times for next-generation sequencing results of less than 24 hours